Roche Holdings (RHHBY - Free Report) announced the launch of a next-generation blood glucose (BG) monitoring system, Accu-Chek Guide.
The new monitoring system will enable BG monitoring much simpler thanks to its features like the spill-resistant SmartPack test strip vial, which helps users remove just one strip at a time and avoid spillage or contamination.
Additionally, the Accu-Chek Guide system will provide high levels of accuracy, thereby facilitating better diabetes management.
The system also enables on-board pattern detection that indicated too high or too low BG readings, along with Bluetooth Low Energy connectivity to the Accu-Chek Connect diabetes management solution via a mobile app. Further, this cloud-based solution guarantees secure online data exchange and automatic data logging.
Roche specializes in developing drugs for oncology, immunology and infectious diseases. Apart from providing therapeutic products and services for diverse medical needs, the company focuses on innovative diagnostic solutions for the early detection and treatment of diseases. The company also leads the vitro diagnostics and tissue-based cancer diagnostics markets.
The launch of new systems will help Roche offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues. A volatile business environment in this space is expected to continue, underscoring persistent need for new diagnostic tests.
Roche currently carries a Zacks Rank #4 (Sell). Some better-ranked health care stocks include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Roche Holdings (RHHBY - Free Report) announced the launch of a next-generation blood glucose (BG) monitoring system, Accu-Chek Guide.
The new monitoring system will enable BG monitoring much simpler thanks to its features like the spill-resistant SmartPack test strip vial, which helps users remove just one strip at a time and avoid spillage or contamination.
Additionally, the Accu-Chek Guide system will provide high levels of accuracy, thereby facilitating better diabetes management.
The system also enables on-board pattern detection that indicated too high or too low BG readings, along with Bluetooth Low Energy connectivity to the Accu-Chek Connect diabetes management solution via a mobile app. Further, this cloud-based solution guarantees secure online data exchange and automatic data logging.
Roche specializes in developing drugs for oncology, immunology and infectious diseases. Apart from providing therapeutic products and services for diverse medical needs, the company focuses on innovative diagnostic solutions for the early detection and treatment of diseases. The company also leads the vitro diagnostics and tissue-based cancer diagnostics markets.
The launch of new systems will help Roche offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues. A volatile business environment in this space is expected to continue, underscoring persistent need for new diagnostic tests.
Roche currently carries a Zacks Rank #4 (Sell). Some better-ranked health care stocks include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RHHBY - FREE
Get the latest research report on PCRX - FREE
Get the latest research report on CORT - FREE
Get the latest research report on ANIP - FREE